Sirius Medical Announces Pintuition Probe Resterilization Clearance

Sirius Medical, a leader in value-based healthcare and surgical marker navigation received 510(k) clearance early in 2023 for their Sirius Pintuition® Probe, used during surgery, to be resterilized by users in STERRAD NX and NX100 systems.

Pintuition is a surgical marker navigation system that provides surgeons with both distance and direction to non-palpable tumors with exceptional accuracy. Patients benefit from enhanced diagnostic accuracy, reduced procedure times, and improved treatment planning.

Users now have the flexibility to choose either to only sterilize, sterilize and cover with a sterile sheath or only use a sterile sheath when using the Pintuition Probe, further broadening the acceptability of the technology and lowering access barriers.

“This FDA clearance is in line with the values we are bringing to our customers worldwide, simplicity, flexibility and accessibility, and affordability,” says Bram Schermers, CEO Sirius Medical. “At Sirius Medical we take pride in listening to our customers bringing continuous product enhancement to help deliver cost-efficient and better patient care with ease of use.”

The company also recently announced their partnership with Surgeons Choice and Surgical Supplies to provide the Australian and New Zealand surgical communities with surgical marker navigation.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”